Interview: Novartis's Big Hopes For Beovu
Drug Gets EU Okay For Wet AMD
After a strong start in the US, Novartis is now ready to take on Bayer's wet age-related macular degeneration blockbuster Eylea in Europe.
You may also be interested in...
The German major's two leading products continue to perform well but there are not many potential blockbusters in the pipeline.
Novartis has been tipped to regain dominance in AMD, but Bayer/Regeneron have also gained 12-week dosing approval.
Regeneron's blockbuster AMD biologic Eylea improved its ability to compete with future longer-acting VEGF inhibitors with a label supporting every dosing every 12 weeks; the company's less frequent regimen cleared FDA five days after receiving a complete response letter.